Abstract. The aim of the present study was to investigate the expression and role of microRNA-18a-5p (miR-18a-5p) during the formation of hypertrophic scar (HS), and to further explore the molecular mechanisms involved. Downregulation of miR-18a-5p in HS tissues and human HS fibroblasts (hHSFs) was detected by reverse transcription-quantitative polymerase chain reaction. The binding sites between miR-18a-5p and the 3'-untranslated region of SMAD family member 2 (Smad2) were predicted by TargetScan and confirmed by dual-luciferase reporter assay. To investigate the role of miR-18a-5p in HS formation, the effects of miR-18a-5p downregulation or upregulation on hHSFs were subsequently determined. Cell proliferation was detected by an MTT assay, while cell apoptosis was measured by flow cytometry. In addition, the protein expression levels of Smad2, Collagen I (Col I) and Col III were examined by western blot assay. The findings indicated that miR-18a-5p downregulation in hHSFs significantly promoted the cell proliferation, decreased cell apoptosis and enhanced the expression levels of Smad2, Col I and Col III protein and mRNA, whereas miR-18a-5p upregulation in hHSFs exerted opposite effects. Notably, the effects of miR-18a-5p upregulation on hHSFs were eliminated by Smad2 upregulation. In conclusion, the data indicated that miR-18a-5p was downregulated during HS formation, and its upregulation repressed scar fibroblast proliferation and extracellular matrix deposition by targeting Smad2. Therefore, miR-18a-5p may serve as a novel therapeutic target for the treatment of HS.

Introduction

Hypertrophic scarring is a common complication of severe trauma, burns and surgical operation, resulting in dysfunction and deformity of the affected parts, which affects the quality of life of patients (1-3). In the formation and development of a hypertrophic scar (HS), the main features include the abnormal proliferation of fibroblasts and inhibition of apoptosis, as well as the imbalance of extracellular matrix collagen synthesis and degradation (4-7). Fibroblasts in HS tissue aggregate, and their number greatly increases. The proportion of Collagen I (Col I) and Col III proteins (also known as type 1 and type 3 collagen, respectively) is abnormal and their content is increased during HS formation, which affects the scar appearance and even causes severe deformity and dysfunction. Currently, the main treatment for hypertrophic scar is surgical resection plus superficial X-ray radiation and dot-matrix laser. However, surgical treatment may cause secondary damage, and radiation therapy may cause radiation dermatitis, delayed healing of the incision and risk of skin cancer at the irradiated site (8). Therefore, it is of great significance to further understand the mechanism underlying the occurrence of HSs, and to identify new targets associated with the molecular mechanism for the prevention and treatment of these scars.

MicroRNAs (miRNAs) are endogenous, non-coding single-stranded small RNAs of approximately 22 nucleotides in length (9,10). miRNAs can regulate gene expression through binding to the 3'-untranslated region (3'-UTR) of target mRNAs, and have emerged as key players in a wide array of biological processes, including cell proliferation and apoptosis (11-13). An increasing number of studies have reported that miRNAs are involved in the occurrence and development of HS (14-17). miR-18a-5p has been studied in several types of cancer, including osteosarcoma (18,19), glioma (20), breast cancer (21), prostate cancer (22), malignant melanoma (23), esophageal carcinoma (24), and renal cell carcinoma (25), among others. Furthermore, previous studies have revealed the inhibitory effect of miR-185-5p on cardiac fibrosis (26) and sub-pleural pulmonary fibrosis (27). However, to the best of our knowledge, the expression and functional role of miR-18a-5p in HS formation remain unclear.

Key words: hypertrophic scar, microRNA-18a-5p, Smad2, hypertrophic scar fibroblasts, proliferation, extracellular matrix
Therefore, the aim of the present study was to investigate the expression and role of miR-18a-5p in HS formation. Since fibroblast hyperplasia and extracellular matrix deposition are the main features of HS formation (28,29), the effect of miR-18a-5p on scar fibroblast proliferation and extracellular matrix deposition was further investigated in the current study in order to explore the underlying mechanism by which miR-18a-5p is involved in HS formation.

**Materials and methods**

**Clinical samples.** A total of 40 HS tissues from 40 patients who were subjected to scar excision (age, 27-51 years old; gender ratio, 1:1) and 40 normal skin tissues from 40 patients subjected to auto-skin grafting (age, 28-53 years old; gender ratio, 1:1) were collected at Peking University Shenzhen Hospital (Shenzhen, China) between February 2015 and February 2017. The tissues were immediately stored in liquid nitrogen until further use. For reverse transcription-quantitative PCR (RT-qPCR) analysis, the tissues were homogenized using an ultrasonic pulverizer (MSE Soniprep 150 Plus; MSE centrifuges). Written informed consent was obtained from each patient enrolled in the present study, and the study was approved by the Human Ethical Committee of Peking University Shenzhen Hospital.

**Cell culture.** The human embryonic skin fibroblasts CCC-ESF-1 were obtained from Shanghai Zibo Biological Technology Co., Ltd. (cat. no. YB-ATCC-3084; Shanghai, China). Human HS fibroblasts (hHSFs) were provided by Shanghai Guandao Biological Engineering Co., Ltd. (cat. no. C0618; Shanghai, China). All cells were grown in Dulbecco’s modified Eagle medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Biological Engineering Co., Ltd. (cat. no. C0618; Shanghai, China)) and incubated at 37˚C with 5% CO₂.

**Cell transfection.** hHSFs were transfected with 100 nM miR-18a-5p inhibitor (5'-CUAUCUGACUAGAGCACCUCUA-3'; Guangzhou RiboBio Co., Ltd.), 100 nM inhibitor control (5'-UUCUCCGAUUGUGACACGUUTT-3'; Guangzhou RiboBio Co., Ltd.), 100 nM miR-18a-5p mimic (sense, 5'-UAA GUGGCAUCUAGAGCAGAUAG-3' and anti-sense, 5'-AUC UGACUAGAGCACCUCUAU-3'; Guangzhou RiboBio Co., Ltd.), 100 nM mimic control (sense, 5'-UUCUCGCAU GUGUACACGUUTT-3' and anti-sense, 5'-ACUGCAGAC GGUCCGGAGATT-3'; Guangzhou RiboBio Co., Ltd.), 1 µg Smad2-plasmid (cat. no. sc-421525-ACT; Santa Cruz Biotechnology, Inc.), 1 µg control-plasmid (cat. no. sc-108083; Santa Cruz Biotechnology, Inc.) or 100 nM control plasmid plus 1 µg Smad2-plasmid using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in line with the manufacturer's protocol. At 48 h after transfection, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to determine transfection efficiency.

**RT-qPCR assay.** In order to collect the total RNA from tissues or cells, TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used in line with the manufacturer's protocol. RNA concentration was determined using a NanoDrop™ 2000c Spectrophotometer (Thermo Fisher Scientific, Inc.). For miRNA detection, reverse transcription and qPCR were performed using miScript II Reverse Transcription kit (Qiagen GmbH) and miSCRIPT SYBR Green PCR Kit (Qiagen GmbH), respectively, as per the manufacturer's protocols. For mRNA detection, PrimeScript™ RT reagent kit (Takara Bio, Inc.) was used for reverse transcription, followed by the SYBR Premix Ex Taq™ II (Tli RNaseH Plus) kit (Takara Bio, Inc.) was applied for qPCR analysis, following the manufacturer's protocol. The thermal cycling conditions were as follows: 35 cycles at 95˚C for 15 sec, annealing at 60˚C for 1 min, then chain extension at 72˚C for 1 min and a final extension step at 72˚C for 10 min. U6 and GAPDH were used as the internal controls for miRNA and mRNA, respectively. Primer sequences for PCR were listed as follows: GAPDH forward, 5'-TTTGTTATCTGTGGAAGGACTC-3' and reverse, 5'-GTA GAGGCGAGGATGATGTCT-3'; U6 forward, 5'-GCTTCT GCAGCACATATACTAAAT-3' and reverse, 5'-GTG CAGGAGTCGAGGT-3'; type I collagen forward, 5'-CCC TGATGGAAGATGGGAG-3' and reverse, 5'-GAGCC GGAATGTCTTGTG-3'; Type III collagen forward, 5'-GGA GCTTGCCACTTCTGCG-3' and reverse, 5'-GGGACAC TTCCTTCAACAG-3' and Smad2 forward, 5'-CGTCCATCT TGCCATTCAGC-3' and reverse, 5'-CCTAACCATCCTA ATCGTCCTG-3'. The relative gene expression was quantified using the 2-ΔΔCq method (30).

**Western blot assay.** Radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology) was used to collect the proteins from cells, and bicinchoninic acid protein assay was then conducted to quantify the protein concentration. Equal amount of protein (40 µg/lane) was separated by 12% SDS-PAGE and then transferred to polyvinylidene difluoride membranes. Next, the membranes were blocked with 5% non-fat milk at room temperature for 1.5 h, incubated with primary antibodies: Smad2 (1:1,000; cat. no. 5339; Cell Signaling Technology, Inc.), Col I (1:1,000; cat. no. ab34710; Abcam), Col III (1:1,000; cat. no. Ab7778; Abcam) and β-actin (1:1,000; cat. no. 4970; Cell Signaling Technology, Inc.) at 4˚C overnight. Subsequently, membranes were incubated with anti-rabbit horseradish peroxidase-conjugated immunoglobulin G secondary antibody (cat. no. 7074; 1:2,000; Cell Signaling Technology, Inc.) at room temperature for 2 h. At the end of the experiment, an enhanced chemiluminescence detection system (Applygen Technologies, Inc., Beijing, China) was used to observe the protein bands. For densitometry detection, analysis with ImageJ 1.38X software (National Institutes of Health, Bethesda, MD, USA) was performed.

**Dual-luciferase reporter assay.** Bioinformatics analysis using the TargetScanHuman 7.2 tool (www.targetscan.org/vert_72) was performed to predict the target genes of miR-18a-5p. The results revealed the binding sites between miR-18a-5p and the 3'UTR of Smad2. Next, in order to confirm these binding sites, dual-luciferase reporter assay was conducted (31). Briefly, the Smad2-WT vector with the wild-type 3'-UTR of Smad2 mRNA and the Smad2-MUT vector with the mutated 3'-UTR of Smad2 mRNA were constructed with the dual-luciferase
reporter vector pmiR-RB-REPORT™ (Guangzhou RiboBio Co., Ltd.). Subsequently, hHSFs were co-transfected with miR-18a-5p mimic or mimic control, and with Smad2-WT or Smad2-MUT using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocol. At 48 h after cell transfection, the relative luciferase activity was measured using a dual-luciferase reporter assay system (Promega Corporation) following the manufacturer’s protocols. Luciferase activity was normalized to the Renilla luciferase activity.

**MTT assay.** To determine cell proliferation, an MTT assay was performed. Briefly, hHSFs were seeded into 96-well plates (1x10^4 cells per well), and then transfected with miR-18a-5p inhibitor, inhibitor control, miR-18a-5p mimic, mimic control or miR-18a-5p mimic + Smad2-plasmid for 48 h. Next, 20 µl MTT (5 mg/ml; Sigma-Aldrich; Merck KGaA) was added to each well and cultured at 37˚C with 5% CO2 for a further 4 h. The optical density value at 490 nm was detected using a microplate reader. Experiments were repeated three times.

**Flow cytometry assay.** hHSFs were collected in the logarithmic growth phase and inoculated into 6-well plates at 1x10^5 cells/well. hHSFs were then transfected with miR-18a-5p inhibitor, inhibitor control, miR-18a-5p mimic, mimic control or miR-18a-5p mimic + Smad2-plasmid for 48 h. Then, cell apoptosis was assessed using the Annexin V-FITC Apoptosis Detection kit (cat. no. 70-AP101-100; MultiSciences, Hangzhou, China) and a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA), according to the manufacturer’s protocol. The data were then analyzed using WinMDI software (version 2.5; www.cyto.purdue.edu/flowcyt/software/Catalog.htm).

**Statistical analysis.** Data are expressed as the mean ± standard deviation of experiments conducted at least in triplicate. The SPSS software, version 18.0 (IBM Corp., Armonk, NY, USA) was used to perform statistical analysis. Comparisons between groups were assessed by Student’s t-test, or by one-way analysis of variance and subsequent Tukey’s post-hoc test. P<0.05 was considered to denote a statistically significant difference.

**Results**

miR-18a-5p is downregulated in HS tissues and hHSFs. In order to detect the level of miR-18a-5p in HS tissues and normal skin tissues, as well as in the human embryonic skin fibroblasts CCC-ESF-1 and hHSFs, RT-qPCR analysis was performed. The results demonstrated that, compared with the normal skin tissues, the level of miR-18a-5p was significantly downregulated in HS tissues (Fig. 1A). Furthermore, compared with the normal fibroblasts CCC-ESF-1 and hHSFs, RT-qPCR analysis was performed. The results demonstrated that, compared with the normal skin tissues, the level of miR-18a-5p in HS tissues and normal skin tissues, as well as in the human embryonic skin fibroblasts CCC-ESF-1 and hHSFs, RT-qPCR analysis was performed. The results demonstrated that, compared with the normal skin tissues, the level of miR-18a-5p was significantly downregulated in HS tissues (Fig. 1A). Furthermore, compared with the normal fibroblasts CCC-ESF-1 and hHSFs, the level of miR-18a-5p in hHSFs was significantly decreased (Fig. 1B).

Smad2 is a target of miR-18a-5p. TargetScanHuman 7.2 was used to conduct bioinformatics analysis, and the binding sites between miR-18a-5p and the 3'-UTR of Smad2 were identified (Fig. 2A). Next, the findings of the dual-luciferase reporter
miR-18a-5p inhibition promotes proliferation, inhibits apoptosis and enhances extracellular matrix deposition in hHSFs. Subsequently, in order to investigate the effect of miR-18a-5p downregulation on hHSFs, the hHSFs were transfected with inhibitor control or miR-18a-5p inhibitor for 48 h. The RT-qPCR results indicated that transfection with miR-18a-5p inhibitor significantly decreased the expression of miR-18a-5p in hHSFs, compared with the untransfected control and inhibitor control groups (Fig. 3A). Next, it was observed that, compared with the control groups, miR-18a-5p inhibitor significantly promoted cell proliferation (Fig. 3B), decreased cell apoptosis (Fig. 3C and D), and enhanced the protein (Fig. 4A-D) and mRNA (Fig. 4E-G) expression levels of Smad2 (Fig. 4A, B and E), Col I (Fig. 4A, C and F), and Col III (Fig. 4A, D and G) in hHSFs. These findings suggest that miR-18a-5p inhibitor could enhance extracellular matrix deposition by hHSFs.

miR-18a-5p upregulation inhibits proliferation, induces apoptosis and represses extracellular matrix deposition in hHSFs. Finally, the effect of miR-18a-5p upregulation on hHSFs was investigated, and hHSFs were transfected with miR-18a-5p mimic, mimic control or miR-18a-5p mimic + Smad2-plasmid for 48 h. In addition, in order to confirm the transfection efficiency of Smad2-plasmid, hHSFs were also transfected with control-plasmid or Smad2-plasmid for 48 h. The results confirmed that miR-18a-5p mimic transfection significantly increased the level of miR-18a-5p in hHSFs (Fig. 5A), while Smad2-plasmid transfection significantly enhanced the mRNA level of Smad2 in hHSFs (Fig. 5B). Further analysis indicated that compared with the control groups, miR-18a-5p mimic transfection significantly
inhibited the proliferation (Fig. 5C) and increased the apoptosis (Fig. 5D and E) of hHSFs, while it markedly reduced the protein (Fig. 6A–D) and mRNA (Fig. 6E–G) expression levels of Smad2 (Fig. 6A, B and E), Col I (Fig. 6A, C and F), and Col III (Fig. 6A, D and G) in hHSFs. Notably, upon co-transfection of cells with miR-18a-5p mimic and Smad2-plasmid, all the effects of miR-18a-5p mimic on hHSFs were significantly reversed by the Smad2 overexpression (Figs. 5C–E and 6). These findings suggest that miR-18a-5p mimic can reduce extracellular matrix deposition by hHSFs.

**Discussion**

In the present study, miR-18a-5p was demonstrated to be significantly downregulated in HS tissues and hHSFs. In addition, the results revealed that Smad2 is a target of miR-18a-5p, and that it was upregulated in HS tissues and hHSFs. Further analysis indicated that miR-18a-5p downregulation significantly promoted cell proliferation and decreased cell apoptosis, as well as enhanced the expression levels of Smad2, Col I and Col III in hHSFs. By contrast, miR-18a-5p upregulation...
Li et al.: miR‑18a‑5p IN HYPERTROPHIC SCAR FORMATION

Significantly inhibited hHSF proliferation, increased cell apoptosis, and reduced the expression levels of Smad2, Col I and Col III in hHSFs. All the effects of miR‑18a‑5p upregulation on hHSFs were significantly reversed by Smad2 overexpression. Taken together, the data suggested that the miR‑18a‑5p/Smad2 axis may be a potential therapeutic target for HS treatment.

HS formation does not only cause cosmetic disfigurement of the human body, but also leads to discomfort, such as pain and itching, and even serious deformity and loss of function.
affecting the patient’s quality of life (29,30,32‑34). Therefore, the formation mechanism and treatment methods of HSs have received increasing attention, and methods for effectively eliminating scars have great clinical significance. Current research has confirmed the important role of miRNAs in the development of skin wound repair and skin diseases (35,36), while numerous studies have also reported the important involvement of miRNAs in HS formation (14‑17). miR‑18a‑5p, which has been well studied in cancer, serves a critical role in the regulation of cell growth (18‑25). As fibroblast hyperplasia and extracellular matrix deposition are the main features of HS formation (28,29), it was hypothesized in the present study that miR‑18a‑5p may also serve an important role in the formation of HS.

Initially, the expression of miR‑18a‑5p in HS and normal skin tissues was measured, and the results indicated that
miR-18a-5p was significantly downregulated in HS tissues. However, it is worth noting that the age of patients who participated in the current study ranged between 27 and 51 years. Since age affects the characteristics of scar tissue and the quality of life of patients (37,38), the wide age range of patients enrolled in the present study was a limitation of the study. The level of miR-18a-5p in the human embryonic skin fibroblasts (hHSFs) was also detected in the current study using RT-qPCR, and the results indicated that miR-18a-5p was significantly downregulated in hHSFs. Subsequently, Smad2 was identified to be a target of miR-18a-5p. Consistent with the findings of a previous study (39), it was observed herein that Smad2 was significantly upregulated in HS tissues. An earlier study reported that silencing of Smad2 gene expression was able to inhibit the TGF-β signaling pathway and thus reduce HS formation (40). The Smad2/3-TGF-β1 signaling pathway serves a key role in the regulation of target gene transcription, matrix protein production (including fibronectin and collagen) and extracellular matrix synthesis and degradation (41,42).

A previous study demonstrated that miR-486-5p inhibited the proliferation, induced apoptosis and G1/S phase arrest in hHSFs by targeting Smad2 (43). In the present study, the effect of miR-18a-5p on the proliferation of hHSFs was investigated. Downregulation of miR-18a-5p in hHSFs significantly promoted the proliferation and inhibited the apoptosis of hHSFs, whereas miR-18a-5p upregulation inhibited the proliferation and increased the apoptosis of hHSFs. All the effects of miR-18a-5p upregulation on the proliferation and apoptosis of hHSFs were significantly reversed by Smad2 overexpression. Conversely, previous studies have indicated that miR-18a-5p promoted the cell proliferation in certain epithelial cells (18,25), while another study has reported that Smad2 suppressed the proliferation of epithelial cells. These contradictory results may be due to the different functions of miRNAs in different microenvironments, and may also be caused by the varying sensitivity of different genes to different signaling pathways under specific conditions. For instance, miR-18a-5p may inhibit the endothelial-mesenchymal transition and cardiac fibrosis through repressing Notch2 pathway (26). In addition, miR-18a-5p induced intrinsic keratinocyte apoptosis in patients with toxic epidermal necrolysis through downregulating BCL2L10 expression (44). miR-18a-5p was also able to promote MG-63 osteosarcoma cell invasion and migration by directly regulating the expression of interferon regulatory factor 2 (21). However, the specific mechanisms of the different roles of miR-18a-5p/Smad2 in epithelial cells and fibroblasts require further in-depth research.

Collagen deposition caused by collagen metabolism disorder is one of the main pathological bases of HS. Collagen is the main component of extracellular matrix and is mainly secreted by skin fibroblasts. Increased expression of Col I and Col III has been detected in the skin scar tissues following trauma (45). In the present study, the effect of miR-18a-5p on extracellular matrix production was also explored in HHSFs. As expected, the data demonstrated that miR-18a-5p downregulation significantly enhanced the expression levels of Col I and Col III in HHSFs, while miR-18a-5p upregulation resulted in the opposite effect. It is worth mentioning that the effects of miR-18a-5p upregulation on Col I and Col III expression in hHSFs were significantly reversed by Smad2 overexpression. However, extracellular matrix deposition was only investigated by western blot assay in the present study, whereas it would be more appropriate to characterize ECM deposition using immunochemistry or immunofluorescence, which is thus a limitation of the present study.

In conclusion, to be best of our knowledge, the present study is the first to reveal that miR-18a-5p is downregulated in HS, and that its upregulation inhibited hHSF proliferation, promoted apoptosis, and reduced Col I and Col III expression levels in hHSFs by targeting Smad2. Therefore, miR-18a-5p may serve as a novel target for the diagnosis and treatment of HS. However, the present study is only a preliminary investigation of the role of miR-18a-5p in HSs. In order to verify the study conclusions, more in-depth research is necessary. For example, the sample size examined was small, and thus the expression of miR-18a-5p in larger HS tissue samples should be analyzed. Furthermore, the correlation between the expression of miR-18a-5p and the clinical features of HS patients, as well as the expression and role of Smad2 in HS, should be further investigated. Besides, the specific mechanism of the positive regulation of Col I and Col III expression levels by Smad2 observed in the present study needs further exploration. Finally, in vivo studies should be performed to confirm these findings. These issues will be addressed in future studies.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

TSL contributed to the study design, data collection, statistical analysis, data interpretation and manuscript preparation. YGW and DDL contributed to data collection and data interpretation. LDZ contributed to statistical analysis and literature search. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from each patient enrolled in the present study, and the study was approved by Human Ethical Committee of Peking University Shenzhen Hospital (Guangdong, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
miR‑18a‑5p inhibits sub‑pleural SREBP1, targeted by miR‑18a‑5p, β et al: 23.

10.

7.

6.

4.

2.

1.

miR‑18a‑5p inhibits endothelial-mesenchymal chyonal transition and cardiac fibrosis through the Notch2 pathway. Biochem Biophys Res Commun 491: 329‑336, 2017.

Zhang Q, Ye H, Xiang F, Song LJ, Zhou LL, Cai PC, Zhang JC, Yu F, Shi HZ, Su Y, et al: miR‑18a‑5p inhibits sub‑pleural pulmonary fibrosis by targeting TGF‑β receptor II. Mol Ther 25: 738‑738, 2017.

Tredget EE, Nedelee B, Scott PG and Ghahary A: Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Surg Clin North Am 77: 701‑730, 1997.

Syed F, Ahmadi E, Igbal SA, Singh S, McGrouther DA and Bayat A: Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralvascular and extraskeletal sites: Clinical implications for lesion site-directed therapy. Br J Dermatol 164: 83‑96, 2011.

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(‑Delta Delta C(T)) method. Methods 25: 402‑408, 2001.

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real‑time quantitative PCR and the 2(‑Delta Delta C(T)) method. Methods 25: 402‑408, 2001.

Schneider JC, Holavanahalli R, Helm P, Goldstein R and Kowalske K: Contractures in burn injury: Defining the problem. J Burn Care Res 27: 508‑514, 2006.

Aberdam D, Candi E, Knight RA and Melino G: miRNAs, ‘sternness’ and skin. Trends Biochem Sci 33: 583‑591, 2008.

Bottchareva NV: MicroRNA/miRNA regulatory networks in the control of skin development and regeneration. Cell Cycle 11: 468‑474, 2012.

Butzlæar U, Ulrich MM, Mink van der Molen AB, Niessen FB and Beelen RH: Currently known risk factors for hypertrophic skin scarring: A review. J Plast Reconstr Aesthet Surg 69: 163‑169, 2016.

Xiao YY, Sun Y, Zhu B, Wang K, Liang P, Liu W, Fu J, Zheng S, Xiao S and Xia Z: Risk factors for hypertrophic burn scar pain, pruritus, and paresthesia development. Wound Repair Regen 26: 172‑181, 2018.

Qi J, Liu Y, Hu K, Zhang Y, Wu Y and Zhang X: MicroRNA‑26a inhibits hyperlastic scar formation by targeting Smad2. Exp Ther Med 15: 4332‑4338, 2018.

Yin L, Zhao X, Ji S, He C, Wang G, Tang C, Gu S and Yin C: The use of gene activated matrix to mediate effective Smad2 gene silencing against hypertrophic scar. Biomaterials 35: 2488‑2498, 2014.

Cao S, Xiao L, Rao JN, Zou T, Liu L, Zhang D, Turner DJ, Gersonne M and Wolf JY: Inhibition of Smurf2 translation by miR‑322‑5p modulates TGF‑β/Smad2 signaling and intestinal epithelial homeostasis. Mol Biol Cell 25: 1234‑1243, 2014.

Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang G, Wang J and Lu J: MiR‑206 suppresses epithelial mesenchymal transition by targeting TGF‑β signaling in estrogen receptor positive breast cancer. Oncotarget 7: 42537‑42548, 2016.

Shi Y, Wang L, Yu P, Liu Y and Chen W: MicroRNA‑486‑5p inhibits the growth of human hypertrophic scar fibroblasts by regulating Smad2 expression. Mol Med Rep 19: 453‑459, 2018.

Zhang Z, Qian W, Feng F, Cao Q, Li Y, Hou Y, Zhang L and Fan J: Upregulated lncRNA CASC2 may inhibit malignant melanoma development through regulating miR‑18a‑5p/RUNX1. Oncol Res 27: 371‑377, 2019.

24. Zhang W, He W, Gao J, Wang Y, Zang W, Dong Z and Zhao G: RETRACTED: The long noncooding RNA CASC2 inhibits tumorigenesis through modulating the expression of PTEN by targeting miR‑18a‑5p in esophageal carcinoma. Exp Cell Res 361: 30‑38, 2017.

25. Zhou L, Li Z, Pan X, Lai Y, Quan J, Zhao L, Xu J, Xu W, Guan X, Li H, et al: Identification of miR‑18a‑5p as an oncogene and prognostic biomarker in RCC. Am J Transl Res 10: 1874‑1886, 2018.

26. Geng H and Guan J: MiR‑18a‑5p inhibits endothelial-mesenchymal chyonal transition and cardiac fibrosis through the Notch2 pathway. Biochem Biophys Res Commun 491: 329‑336, 2017.

27. Zhang Q, Ye H, Xiang F, Song LJ, Zhou LL, Cai PC, Zhang JC, Yu F, Shi HZ, Su Y, et al: miR‑18a‑5p inhibits sub‑pleural pulmonary fibrosis by targeting TGF‑β receptor II. Mol Ther 25: 738‑738, 2017.

28. Tredget EE, Nedelee B, Scott PG and Ghahary A: Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Surg Clin North Am 77: 701‑730, 1997.

29. Syed F, Ahmadi E, Igbal SA, Singh S, McGrouther DA and Bayat A: Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralvascular and extraskeletal sites: Clinical implications for lesion site-directed therapy. Br J Dermatol 164: 83‑96, 2011.

30. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(‑Delta Delta C(T)) method. Methods 25: 402‑408, 2001.

31. Lu Q, Guo Z and Qian H: Role of microRNA‑150‑5p/SRC1IN1 axis in the progression of breast cancer. Exp Ther Med 17: 2221‑2229, 2019.

32. Aarabi S, Longaker MT and Gunner GC: Hypertrophic scar formation following burns and trauma: New approaches to treat. PLoS Med 4: e234, 2007.

33. Gangemi EN, Gregori D, Berchialla P, Zingarelli E, Cairo M, Bollero D, Ganem J, Capoccelli R, Cuccuru F, Cassano P, et al: Epidemiology and risk factors for pathologic scarring after burn wounds. Arch Facial Plast Surg 10: 93‑102, 2008.

34. Schneider JC, Holavanahalli R, Helm P, Goldstein R and Kowalske K: Contractures in burn injury: Defining the problem. J Burn Care Res 27: 508‑514, 2006.

35. Aberdam D, Candi E, Knight RA and Melino G: miRNAs, ‘sternness’ and skin. Trends Biochem Sci 33: 583‑591, 2008.

36. Bottchareva NV: MicroRNA/miRNA regulatory networks in the control of skin development and regeneration. Cell Cycle 11: 468‑474, 2012.

37. Butzlæar U, Ulrich MM, Mink van der Molen AB, Niessen FB and Beelen RH: Currently known risk factors for hypertrophic skin scarring: A review. J Plast Reconstr Aesthet Surg 69: 163‑169, 2016.

38. Xiao YY, Sun Y, Zhu B, Wang K, Liang P, Liu W, Fu J, Zheng S, Xiao S and Xia Z: Risk factors for hypertrophic burn scar pain, pruritus, and paresthesia development. Wound Repair Regen 26: 172‑181, 2018.

39. Qi J, Liu Y, Hu K, Zhang Y, Wu Y and Zhang X: MicroRNA‑26a inhibits hyperlastic scar formation by targeting Smad2. Exp Ther Med 15: 4332‑4338, 2018.

40. Yin L, Zhao X, Ji S, He C, Wang G, Tang C, Gu S and Yin C: The use of gene activated matrix to mediate effective Smad2 gene silencing against hypertrophic scar. Biomaterials 35: 2488‑2498, 2014.

41. Cao S, Xiao L, Rao JN, Zou T, Liu L, Zhang D, Turner DJ, Gersonne M and Wolf JY: Inhibition of Smurf2 translation by miR‑322‑5p modulates TGF‑β/Smad2 signaling and intestinal epithelial homeostasis. Mol Biol Cell 25: 1234‑1243, 2014.

42. Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang G, Wang J and Lu J: MiR‑206 suppresses epithelial mesenchymal transition by targeting TGF‑β signaling in estrogen receptor positive breast cancer. Oncotarget 7: 42537‑42548, 2016.

43. Shi Y, Wang L, Yu P, Liu Y and Chen W: MicroRNA‑486‑5p inhibits the growth of human hypertrophic scar fibroblasts by regulating Smad2 expression. Mol Med Rep 19: 5023‑5029, 2018.

44. Ichihara A, Wang Z, Jinmin M, Izuno Y, Shimozono N, Yamane K, Fujisawa A, Moriya C, Fukushima S, Inoue Y and Ihn H: Upregulation of miR‑18a‑5p contributes to epidermal necrosis in severe drug eruptions. J Allergy Clin Immunol 133: 1065‑1074, 2014.

45. Zhou R, Zhang Q, Zhang Y, Fu S and Wang C: Aberrant miR‑21and miR‑200b expression and its pro‑fibrotic potential in hypertrophic scars. Exp Cell Res 339: 360‑366, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.